HOUSTON, Dec. 15 (UPI) -- U.S. medical scientists say they've found indolent B cell lymphoma patients respond well to a new three-drug combination therapy.
Scientists have demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development.
Patients suffering from B-cell lymphomas can be treated with antibodies directed against the B-lymphocyte antigen CD20.
... therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults. The new study, published ...
... studying molecular signals that drive B cell lymphoma have found a key biological pathway leading to this type of cancer. The finding may help to break ...
... specificity. Researchers have now identified subpopulations of B cells at the germinal centers which express the proto ... is essential for the formation and maintenance of germinal centers. Their findings have implications for the pathogenesis of B-cell lymphomas ...
... promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers working ... next year. Diffuse large B-cell lymphoma is one of the most common and aggressive forms of non ...
... have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer ... a very good, predictive model of B-cell lymphomas, which can be used to explore not only these and related cancers, but also autoimmune ...
... personalized therapy to tackle follicular B-cell lymphoma, an immune-system malignancy diagnosed ... year. Doctors regard follicular B-cell lymphoma as a chronic, incurable disease. The standard ...
... developed as a cancer treatment for patients with B cell lymphoma, but kidney researchers have shown that this drug also is safe and reduces the amount of protein lost ...
... in all EBV-associated tumors, including B-cell lymphomas and gastric carcinoma, these findings raise the possibility that EBNA1 could play a similar role ...
... ), while others with this genetic defect have problems with B-cell lymphomas. The new study was a collaboration between the laboratories of NIH scientists Ronald Germain, M ...
DLBCL is the most common histologic subtype of the NHLs accounting for about 40% of all NHL. Stage IV or disseminated disease is observed in approximately 40% of patients and is usually characterised ...
... Clinical Activity in Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia [Abstract ... previous treatments for diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and small ...
... : 228 patients with diffuse large B-cell lymphoma, an aggressive form of the disease. Twenty ... of patients. For patients with diffuse large B-cell lymphoma, statin use did not influence outcomes ...
